Literature DB >> 20378012

The osteopontin gene +1239A/C single nucleotide polymorphism is associated with type 1 diabetes mellitus in the Italian population.

A Chiocchetti1, E Orilieri, G Cappellano, N Barizzone, S D' Alfonso, G D' Annunzio, R Lorini, R Ravazzolo, F Cadario, M Martinetti, V Calcaterra, F Cerutti, G Bruno, D Larizza, U Dianzani.   

Abstract

Secreted phosphoprotein 1, also known as Osteopontin (Opn), is a proinflammatory cytokine involved in the TH1 response and is highly expressed in the islets and pancreatic lymph nodes of non-obese diabetic mice before the onset of diabetes. In humans, typing of the +1239A/C single nucleotide polymorphism (SNP) in the 3UTR of the Opn gene (SPP1) showed that +1239C carriers displayed higher Opn serum levels than +1239A homozygotes and a higher risk of developing autoimmune/lymphoproliferative syndrome, multiple sclerosis, and systemic lupus erythematosus. The aim of this work is to evaluate whether +1239A/C is also associated with type 1 diabetes mellitus (T1DM). We typed +1239A/C in an initial cohort of 184 T1DM patients and 361 controls, and confirmed our data in a second cohort of 513 patients and 857 controls. In both cohorts, +1239C carriers displayed a significantly higher risk of T1DM than +1239A homozygotes (combined cohorts: OR=1.63, 95 percent CI: 1.34-1.97). Clinical analysis did not detect any differences between patients carrying or not +1239C in terms of gender distribution and age at T1DM diagnosis. These data suggest that SPP1 variants marked by +1239C are associated with T1DM development in the Italian population. The predisposing effect may depend on its effect on Opn levels.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20378012     DOI: 10.1177/039463201002300124

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  11 in total

1.  Overexpression of osteopontin in hepatocellular carcinoma and its relationships with metastasis, invasion of tumor cells.

Authors:  Fan Lin; Yuyuan Li; Jie Cao; Shaofeng Fan; Jifeng Wen; Guanghui Zhu; Hong Du; Yanxiao Liang
Journal:  Mol Biol Rep       Date:  2010-12-29       Impact factor: 2.316

2.  Quantitative genetic study of the circulating osteopontin in community-selected families.

Authors:  S Ermakov; A Leonov; S Trofimov; I Malkin; G Livshits
Journal:  Osteoporos Int       Date:  2010-10-22       Impact factor: 4.507

3.  The osteopontin transgenic mouse is a new model for Sjögren's syndrome.

Authors:  Sehba Husain-Krautter; Jill M Kramer; Wentian Li; Benchang Guo; Thomas L Rothstein
Journal:  Clin Immunol       Date:  2015-01-05       Impact factor: 3.969

Review 4.  Interstitial calcinosis in renal papillae of genetically engineered mouse models: relation to Randall's plaques.

Authors:  Xue-Ru Wu
Journal:  Urolithiasis       Date:  2014-08-06       Impact factor: 3.436

5.  The role of osteopontin (OPN/SPP1) haplotypes in the susceptibility to Crohn's disease.

Authors:  Jürgen Glas; Julia Seiderer; Corinna Bayrle; Martin Wetzke; Christoph Fries; Cornelia Tillack; Torsten Olszak; Florian Beigel; Christian Steib; Matthias Friedrich; Julia Diegelmann; Darina Czamara; Stephan Brand
Journal:  PLoS One       Date:  2011-12-29       Impact factor: 3.240

6.  The impact of osteopontin gene variations on multiple sclerosis development and progression.

Authors:  Cristoforo Comi; Giuseppe Cappellano; Annalisa Chiocchetti; Elisabetta Orilieri; Sara Buttini; Laura Ghezzi; Daniela Galimberti; Franca Guerini; Nadia Barizzone; Franco Perla; Maurizio Leone; Sandra D'Alfonso; Domenico Caputo; Elio Scarpini; Roberto Cantello; Umberto Dianzani
Journal:  Clin Dev Immunol       Date:  2012-09-11

7.  Variations of the UNC13D gene in patients with autoimmune lymphoproliferative syndrome.

Authors:  Maurizio Aricò; Elena Boggio; Valentina Cetica; Matteo Melensi; Elisabetta Orilieri; Nausicaa Clemente; Giuseppe Cappellano; Sara Buttini; Maria Felicia Soluri; Cristoforo Comi; Carlo Dufour; Daniela Pende; Irma Dianzani; Steven R Ellis; Sara Pagliano; Stefania Marcenaro; Ugo Ramenghi; Annalisa Chiocchetti; Umberto Dianzani
Journal:  PLoS One       Date:  2013-07-01       Impact factor: 3.240

8.  Investigation of osteopontin levels and genomic variation of osteopontin and its receptors in Type 1 diabetes mellitus.

Authors:  Z Karamizadeh; E Kamali Sarvestani; F Saki; H Karamifar; G H Amirhakimi; M H Namavar Shooshtarian; S Ashkani-Esfahani
Journal:  J Endocrinol Invest       Date:  2013-09-27       Impact factor: 5.467

Review 9.  Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes.

Authors:  Florian Kahles; Hannes M Findeisen; Dennis Bruemmer
Journal:  Mol Metab       Date:  2014-03-22       Impact factor: 7.422

Review 10.  Osteopontin at the Crossroads of Inflammation and Tumor Progression.

Authors:  Luigi Mario Castello; Davide Raineri; Livia Salmi; Nausicaa Clemente; Rosanna Vaschetto; Marco Quaglia; Massimiliano Garzaro; Sergio Gentilli; Paolo Navalesi; Vincenzo Cantaluppi; Umberto Dianzani; Anna Aspesi; Annalisa Chiocchetti
Journal:  Mediators Inflamm       Date:  2017-07-09       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.